Dr David Farrugia : Medical oncology

Home
Dr David Farrugia

Not Fee assured
Verified account
Open Referral network

Overview

Specialises in

Lower GI

Skin

Urology

Offers

Video and telephone consultations
Home chemotherapy

About me

I am a Medical Oncologist with 23 years experience at Consultant level and specialise in the medical treatment of a range of cancers. I am the only provider of private Medical Oncology services in Gloucestershire. I trained in several London teaching Hospitals including the Royal Marsden, St Bartholomew's and Guy's Hospital and also undertook a research degree (PhD) at the Institute of Cancer Research, Royal Marsden Hospital, London. Research continues to be an integral part of my practice in order to drive new developments in care for my patients as well as providing them with the latest and most cutting-edge treatments.

I am a leader in the introduction of targeted biological therapies and Immunotherapy in a range of solid tumours in our service. I am also leading on the introduction of molecular profiling to introduce new treatments based on the genetic signature rather than site of origin.

Areas of interest

Investigation and treatment of Cancer of Unknown primary, Neuroendocrine tumours; Lung cancer; Malignant Mesothelioma; Malignant melanoma; Colorectal (bowel) cancer; Kidney (renal) cancer.

DURING THE COVID-19 OUTBREAK:

I continue to offer private consultations face to face, by video-conferencing and phone.
I am accepting new patients.
I can provide chemotherapy, targeted therapies and immunotherapy treatment in the home or outpatient setting to maximise self-isolation and distancing for vulnerable patients.

Medical secretaries

Tala Scott
Cheltenham General Hospital Sandford Road CHELTENHAM GL53 7AN
0300 422 4016
07796 577481
0300 422 3506
Drfarrugia.pp@nhs.net

About me

Current NHS consultant posts held

Consultant Medical Oncologist
Gloucestershire Oncology Centre
Cheltenham General Hospital

Research interests

Biological Therapies.
Immunotherapy.
Predictors of response to treatment (Precision medicine)
Supportive care of patients undergoing anti-cancer therapy.
Patient decision aids in Cancer of Unknown Primary

Awards received

3. ASCO Merit Award at the May 1999 Annual meeting in Atlanta, Georgia, for a poster discussion presentation entitled “Genomic Study Of Patients With Advanced Colorectal Cancer Treated With Raltitrexed (‘Tomudex’)”.

Chief Medical Officer’s Award for services to Commercial Research 2015.

Abbvie Pharmaceuticals Gold Star Award for recruitment into Lung Cancer Studies 2015.

Shortlisted for a Gloucestershire Hospitals NHS Foundation Trust Staff Award for Services to Research 2017.

(Additional) Languages spoken

Publications

FARRUGIA DC, NORMAN AR, et al. Unknown Primary Carcinoma: Randomised Studies are needed to identify optimal Treatments and their Benefits. Eur J of Cancer. 1996; 32A: 2256-2261.

D C FARRUGIA, A R NORMAN AND D CUNNINGHAM. Single Agent Infusional 5-FU is not Effective Second Line Therapy after Tomudex in Advanced Colorectal Cancer. Eur J of Cancer. 1998; 34(7): 987-991..

FORD, H E, MITCHELL F, CUNNINGHAM D, FARRUGIA D C et al. "Patterns of elevation of plasma 2'-deoxyuridine, a surrogate marker of thymidylate synthase (TS) inhibition, after administration of two different schedules of 5-fluorouracil and the specific TS inhibitors raltitrexed (Tomudex) and ZD9331." Clin Cancer Res 2002; 8(1): 103-9.

FARRUGIA D, FORD H, et al. Thymidylate Synthase Expression in Advanced Colorectal Cancer Predicts for Response to Raltitrexed. Clin Cancer Res 2003; 9: 792-801.

GUGLANI S, FARRUGIA D, et al. Reversible Life-Threatening Encephalopathy In The Absence Of Hepatic Failure Following Conventional Doses Of Docetaxel. Clin Oncol (R Coll Radiol). 2003; 15(3): 160-1.

MEDLEY, L., A. N. MOREL, D FARRUGIA et al. (2011). "Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours." Br J Cancer 104(7): 1067-70.

PAYNE, M. J., K. ARGYROPOULOU, LORIGAN, P., MCALEER, J. J., FARRUGIA, D., et al. (2013). "Phase II Pilot Study of Intravenous High-Dose Interferon With or Without Maintenance Treatment in Melanoma at High Risk of Recurrence." J Clin Oncol. Dec 16.

DECATRIS, M. P., FARRUGIA, D. et al. (2016). "Clinician Perspective on Molecular Profiling of Non-Small-Cell Lung Cancer." J Clin Oncol 34(8): 884-886.

T IVESON, RS KERR, et al. (2018). '3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial', Lancet Oncol, 19: 562-78.

CORRIE P.G, MARSHALL A, et al. on behalf of the AVAST-M Investigators. (2018). Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial. Ann Oncol, 29: 1843-52.

PETER VINK, IGNACIO DELGADO MIGNORANCE et al. “Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Vaccine in Adults with Solid Tumors, Vaccinated Before or During Chemotherapy: Randomized Trial”. Accepted for publication in Cancer, October 2018.

Courses offered to GPs

Update lectures to GPs on Cancer of Unknown Primary, Skin cancer, Kidney cancer, Lung Cancer, neuroendocrine tumours.

My qualifications & training

Qualifications

MD University of Malta 1987
PhD University of London 1998
FRCP Royal College of Physicians, London 2004

Additional training

CCST Medical Oncology JCHMT, London 2000

GMC registration

Reference number 3641426

Affiliations / memberships

1. American Association of Clinical Oncology (ASCO)
2. Association of Cancer Physicians (ACP), UK
3. European Society of Medical Oncology (ESMO)
4. British Thoracic Oncology Group (BTOG)
5. EORTC melanoma group
6. UK Melanoma FOCUS Group
7. UK Neuroendocrine Tumour Study Group (UKINETS)

My private practice

Information for healthcare professionals (Bupa patients only, last 12 months)

Procedures completed

X0004
Clinical supervision and planning for the delivery of chemotherapy and/or systemic anti-cancer therapy for 1-28 days - (5-50)

Spire South Bank Hospital (5-50)
X0003
Clinical supervision and planning for the delivery of chemotherapy and/or systemic anti-cancer therapy for 1-21 days - (5-50)

Spire South Bank Hospital (1-5)

Report this page Print page

Finder

Note: